Carisma Therapeutics Full Year 2024 Earnings: Misses Expectations

Carisma Therapeutics (NASDAQ:CARM) Full Year 2024 Results

Key Financial Results

• Revenue: US$19.6m (up 32% from FY 2023).
• Net loss: US$60.5m (loss narrowed by 30% from FY 2023).
• US$1.46 loss per share (improved from US$2.59 loss in FY 2023).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Carisma Therapeutics Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 8.3%. Earnings per share (EPS) also missed analyst estimates by 22%.

Looking ahead, revenue is expected to decline by 57% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 19%.

Performance of the American Biotechs industry.

The company's shares are down 42% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 5 warning signs with Carisma Therapeutics (at least 2 which can't be ignored), and understanding them should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.